CIBMTR Reporting Implementation Guide - Local Development build (v0.1.6). See the Directory of published versions
Active as of 2023-05-05 |
<ValueSet xmlns="http://hl7.org/fhir">
<id value="med-alemtuzumab-vs"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><ul><li>Include these codes as defined in <a href="http://www.nlm.nih.gov/research/umls/rxnorm"><code>http://www.nlm.nih.gov/research/umls/rxnorm</code></a><table class="none"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td>117055</td><td>alemtuzumab</td></tr><tr><td>284679</td><td>Campath</td></tr><tr><td>1594659</td><td>Lemtrada</td></tr><tr><td>828267</td><td>1 ML alemtuzumab 30 MG/ML Injection [Campath]</td></tr><tr><td>1594663</td><td>1.2 ML alemtuzumab 10 MG/ML Injection [Lemtrada]</td></tr><tr><td>1594657</td><td>alemtuzumab 10 MG/ML</td></tr><tr><td>1594660</td><td>alemtuzumab 10 MG/ML [Lemtrada]</td></tr><tr><td>1656640</td><td>alemtuzumab 10 MG/ML Injection [Lemtrada]</td></tr><tr><td>1656628</td><td>alemtuzumab 30 MG/ML</td></tr><tr><td>1656631</td><td>alemtuzumab 30 MG/ML [Campath]</td></tr><tr><td>1656635</td><td>alemtuzumab 30 MG/ML Injection [Campath]</td></tr><tr><td>1164265</td><td>alemtuzumab Injectable Product</td></tr><tr><td>1656629</td><td>alemtuzumab Injection</td></tr><tr><td>1656632</td><td>alemtuzumab Injection [Campath]</td></tr><tr><td>1656637</td><td>alemtuzumab Injection [Lemtrada]</td></tr><tr><td>1172298</td><td>Campath Injectable Product</td></tr><tr><td>1594662</td><td>Lemtrada Injectable Product</td></tr></table></li></ul></div>
</text>
<url
value="http://fhir.nmdp.org/ig/cibmtr-reporting/ValueSet/med-alemtuzumab-vs"/>
<version value="0.1.6"/>
<name value="RxNormAlemtuzumabVS"/>
<title value="RxNorm - Alemtuzumab"/>
<status value="active"/>
<experimental value="true"/>
<date value="2023-05-05T10:07:01-05:00"/>
<publisher
value="The Medical College of Wisconsin, Inc. and the National Marrow Donor Program"/>
<contact>
<name
value="The Medical College of Wisconsin, Inc. and the National Marrow Donor Program"/>
<telecom>
<system value="url"/>
<value value="http://www.cibmtr.org"/>
</telecom>
</contact>
<contact>
<name value="Bob Milius"/>
<telecom>
<system value="email"/>
<value value="bmilius@nmdp.org"/>
</telecom>
</contact>
<description value="RxNorm codes for Alemtuzumab"/>
<compose>
<include>
<system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
<concept>
<code value="117055"/>
<display value="alemtuzumab"/>
</concept>
<concept>
<code value="284679"/>
<display value="Campath"/>
</concept>
<concept>
<code value="1594659"/>
<display value="Lemtrada"/>
</concept>
<concept>
<code value="828267"/>
<display value="1 ML alemtuzumab 30 MG/ML Injection [Campath]"/>
</concept>
<concept>
<code value="1594663"/>
<display value="1.2 ML alemtuzumab 10 MG/ML Injection [Lemtrada]"/>
</concept>
<concept>
<code value="1594657"/>
<display value="alemtuzumab 10 MG/ML"/>
</concept>
<concept>
<code value="1594660"/>
<display value="alemtuzumab 10 MG/ML [Lemtrada]"/>
</concept>
<concept>
<code value="1656640"/>
<display value="alemtuzumab 10 MG/ML Injection [Lemtrada]"/>
</concept>
<concept>
<code value="1656628"/>
<display value="alemtuzumab 30 MG/ML"/>
</concept>
<concept>
<code value="1656631"/>
<display value="alemtuzumab 30 MG/ML [Campath]"/>
</concept>
<concept>
<code value="1656635"/>
<display value="alemtuzumab 30 MG/ML Injection [Campath]"/>
</concept>
<concept>
<code value="1164265"/>
<display value="alemtuzumab Injectable Product"/>
</concept>
<concept>
<code value="1656629"/>
<display value="alemtuzumab Injection"/>
</concept>
<concept>
<code value="1656632"/>
<display value="alemtuzumab Injection [Campath]"/>
</concept>
<concept>
<code value="1656637"/>
<display value="alemtuzumab Injection [Lemtrada]"/>
</concept>
<concept>
<code value="1172298"/>
<display value="Campath Injectable Product"/>
</concept>
<concept>
<code value="1594662"/>
<display value="Lemtrada Injectable Product"/>
</concept>
</include>
</compose>
</ValueSet>
IG © 2020+ The Medical College of Wisconsin, Inc. and the National Marrow Donor Program
Package nmdp.fhir.cibmtr-reporting#0.1.6 based on FHIR 4.0.1. Generated 2023-05-05
Links: Table of Contents |
QA Report
HL7®, and FHIR® are the registered trademarks of Health Level Seven International
and their use of these trademarks does not constitute an endorsement by HL7.